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Cross-Sectional Associations of Computed Tomography (CT)-Derived
Adipose Tissue Density and Adipokines: The Framingham Heart Study
Jane J. Lee, PhD; Alison Pedley, PhD; Udo Hoffmann, MD, MPH; Joseph M. Massaro, PhD; John F. Keaney, Jr., MD;
Ramachandran S. Vasan, MD; Caroline S. Fox, MD, MPH
Background-—Excess accumulation of abdominal subcutaneous (SAT) and visceral adipose tissue (VAT) is associated with adverse
levels of adipokines and cardiovascular disease risk. Whether fat quality is associated with adipokines has not been ﬁrmly
established. This study examined the association between abdominal SAT and VAT density, an indirect measure of fat quality, with
a panel of metabolic regulatory biomarkers secreted by adipose tissue or the liver independently of absolute fat volumes.
Methods and Results-—We evaluated 1829 Framingham Heart Study participants (44.9% women). Abdominal SAT and VAT density
was estimated indirectly by adipose tissue attenuation using computed tomography. Adipokines included adiponectin, leptin
receptor, leptin, fatty acid-binding protein 4 (FABP-4), retinol-binding protein 4 (RBP-4), and fetuin-A. Fat density was associated
with all the biomarkers evaluated, except fetuin-A. Lower fat density (ie, more-negative fat attenuation) was associated with lower
adiponectin and leptin receptor, but higher leptin and FABP-4 levels (all P<0.0001). SAT density was inversely associated with RPB-
4 in both sexes, whereas the association between VAT density and RPB-4 was only observed in men (P<0.0001). In women, after
additional adjustment for respective fat volume, SAT density retained the signiﬁcant associations with adiponectin, leptin, FABP-4,
and RBP-4; and VAT density with adiponectin only (all P<0.0001). In men, signiﬁcant associations were maintained upon additional
adjustment for respective fat volume (P<0.005).
Conclusions-—Lower abdominal fat density was associated with a proﬁle of biomarkers suggestive of greater cardiometabolic risk.
These observations support that fat density may be a valid biomarker of cardiometabolic risk. ( J Am Heart Assoc. 2016;5:
e002545 doi: 10.1161/JAHA.115.002545)
Key Words: adipokine • adipose tissue • computed tomography • epidemiology
P revalence of abdominal obesity has increased in theUnited States and currently affects more than 54% of US
adults.1 Excess accumulation of abdominal adiposity increases
the risks of type 2 diabetes, hypertension, dyslipidemia, and
metabolic syndrome.2–4 Abdominal adipose tissue including
subcutaneous (SAT) and visceral adipose tissue (VAT) has been
widely recognized as a pathogenic phenotype.2,5,6 In addition,
recent studies suggested that qualitative aspects of adipose
tissue, such as adipocyte size,7 macrophage inﬁltration,8
angiogenesis,9 hypoxia,10 and ﬁbrosis,11 are also associated
with metabolic and cardiovascular disease (CVD).
Computed tomography (CT) imaging techniques allow for
the indirect quantiﬁcation of abdominal fat quality by
assessing the density of adipose tissue by radiographic pixels
that are denoted in Hounsﬁeld units (HU) and referred to as
attenuation.12 Our previous study utilized abdominal SAT and
VAT density as an indirect measure of fat quality to explore
the association with CVD risk factors. In that study, lower fat
density (ie, more-negative CT fat attenuation) was associated
with adverse cardiometabolic risk, including higher blood
pressure, insulin resistance, triglycerides, and lower high-
density lipoprotein levels cross-sectionally.13
To further promote the mechanistic understanding of fat
quality, we sought to explore the cross-sectional associations
between abdominal fat density with a panel of circulating
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biomarkers mainly released by adipose tissue (adiponectin,
leptin receptor, leptin, and fatty acid-binding protein 4 [FABP-
4]) and by both adipose tissue and the liver (retinol-binding
protein 4 [RBP-4] and fetuin-A). On the basis of our previous
ﬁndings regarding the inverse association of abdominal
adipose tissue density with cardiometabolic risk, we hypoth-
esized that lower SAT and VAT density would be associated
with adverse levels of adipokines, even after adjusting for
generalized adiposity (body mass index [BMI]), central obesity
(waist circumference), and respective abdominal adipose
tissue volumes.
Methods
Study Sample
The Framingham Heart Study was initiated in 1948 as a
community-based observational study to explore the associ-
ation between CVDs and related risk factors with lifestyle,
environment, and inheritance.14 The present study drew
participants from the multidetector CT substudy of the Third
Generation Framingham cohort who underwent imaging from
2002 to 2005. Detailed information of the Third Generation
cohort of the Framingham Heart Study has been previously
described elsewhere.15 For the present investigation, we
included participants who had data on (1) abdominal adipose
tissue volume and attenuation evaluated by multidetector
CT; (2) circulating biomarker levels, including adiponectin,
leptin receptor, leptin, FABP-4, RBP-4, and fetuin-A; and (3)
covariates. Among 2117 participants from the initial recruit-
ment of the multidetector CT cohort, 250 participants were
excluded because of a lack of abdominal fat and biomarker
values. An additional 38 participants were excluded because
of missing covariates, resulting in a total of 1829 participants
(86.4% of those eligible) in this investigation. The study
protocol was approved by the institutional review boards of
the Boston University Medical Center and Massachusetts
General Hospital. All participants provided written informed
consent.
Abdominal Subcutaneous and Visceral Adipose
Tissue Volume and Density
A total of 25 consecutive slices of abdomen were obtained
while participants lay in a supine position by an 8-slice
multidetector CT scanner (LightSpeed Ultra; General Electric,
Milwaukee, WI) with a thickness of 5 mm, tube voltage of
120 kVp, and radiation dose of 3 to 5 mSv.12 The assessment
of abdominal adipose tissue quantity and density was
performed by evaluating the CT slides with a three-dimen-
sional (3D) workstation tool (Aquarius 3D Workstation;
TeraRecon Inc, San Mateo, CA). The trained technicians
designated the region of interest by manually outlining the
abdominal muscular wall. Subsequently, the region of SAT and
VAT compartments were automatically identiﬁed based on the
radiographic pixel threshold between 195 and 45 HU
with center attenuation of 120 HU. Mean SAT and VAT
volumes in cm3 and attenuation in HU were recorded.
Previously, high reproducibility of these abdominal CT mea-
surements were conﬁrmed, with inter- and intrareader
reliability greater than 0.99.12
Adipokines
The group of circulating biomarkers produced by adipose tissue
only (adiponectin, leptin receptor, leptin, and FABP-4) and by
both adipose tissue and the liver (RBP-4 and fetuin-A) were
evaluated. Blood samples were collected after a minimum of
8 hours of overnight fasting and analyzed following standard
protocols. Plasma levels of adiponectin, leptin receptor, leptin,
and RBP-4 levels were determined by the ELISA method (R&D
Systems, Minneapolis, MN) with mean interassay coefﬁcients
of variation of 2.23% for adiponectin, 4.01% for leptin receptor,
4.97% for leptin, and 2.18% for RBP-4. Plasma levels of FABP-4
and fetuin-A were assessed by the sandwich ELISA method
(BioVendor Research and Diagnostic Products, Candler, NC)
with mean interassay coefﬁcients of variation of 2.38% for
FABP-4 and 2.52% for fetuin-A.
Measurement of Covariates
BMI was computed as body weight in kilograms divided by
height in meters squared. Waist circumference was assessed
by a measuring tape at the horizontal level of the umbilicus
to the closest 0.25 inch. A series of questionnaires were
administered to document the clinical history and lifestyle
patterns of the participants, including current use of
hormone replacement therapy, current smoking, alcohol
use, and physical activity level. Current smoking was
speciﬁed as those who smoked at least 1 cigarette per
day within the previous year. Participants were considered
moderate-to-heavy drinkers based on the consumption of
>7 drinks/week for women and >14 drinks/week for men.
Physical activity was evaluated using a questionnaire-derived
physical activity score, which incorporated the time individ-
uals participated in different levels of physical activity, taking
into account the required oxygen consumption for each of
the activities.16
Statistical Analysis
We conducted a sex-speciﬁc analysis because of the differ-
ences in women and men regarding fat distribution and the
circulating biomarker levels.13,17 All the adipokines were
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natural logarithmically transformed to normalize their skewed
distributions. Age-adjusted partial Pearson correlation coefﬁ-
cients were computed to examine the association between
abdominal CT fat density and natural log-transformed biomark-
ers. Multivariable-adjusted linear regressions were performed
to assess the association between fat density (independent
variable) and each of the natural log-transformed biomarkers
(dependent variable) with a separate model performed for each
association tested. Multivariable adjustment included age,
hormone replacement therapy (women only), current smoking,
alcohol use, and physical activity score. We also examined
whether the associations were independent of measures of
obesity by additionally adjusting for BMI, waist circumference,
or respective fat volumes. The b-coefﬁcients computed in these
models describe the estimated association in the natural log-
transformed biomarkers for a 5-unit (1-SD) decrement in fat
density.
Tests for sex interaction were also conducted using
multivariable-adjusted linear regression. As a secondary
analysis, the multivariable-adjusted least-square means for
each of the biomarker levels by sex-speciﬁc tertiles of CT fat
volume within tertiles of CT fat density were examined.
A 2-tailed P value less than 0.05 was considered statis-
tically signiﬁcant. We did not further adjust for multiple
testing because the purpose of this investigation was principal
hypothesis generating (ie, to identify potential associations
between abdominal fat density and a panel of adipokines). All
statistical analysis was performed using SAS software (ver-
sion 9.2; SAS Institute Inc., Cary, NC).
Results
Descriptive Characteristics
Clinical, adiposity, biomarker, and lifestyle characteristics of
the 821 women and 1008 men (overall mean age, 45 years)
included in the study are shown in Table 1. Median SAT and
VAT attenuations were 103.3 and 91.5 HU in women and
100.7 and 91.5 HU in men, respectively.
Age-Adjusted Correlations With Abdominal Fat
Density and Adipokines
Age-adjusted, sex-stratiﬁed Pearson correlation coefﬁcients
between abdominal fat density and natural log-transformed
biomarkers are given in Table 2. Higher (ie, more-positive CT
fat attenuation) SAT and VAT density was correlated with
higher levels of adiponectin and leptin receptor (r values
Table 1. Characteristics of Study Population
Characteristics Women (n=821) Men (n=1008)
Age, y 46.1 (5.7) 44.1 (6.3)
Body mass index, kg/m2 26.5 (6.0) 28.1 (4.4)
Waist circumference, cm 90.3 (15.5) 99.4 (11.8)
Subcutaneous adipose tissue, cm3 2985 (1565) 2588 (1226)
Visceral adipose tissue, cm3 1127 (729) 1986 (870)
Subcutaneous adipose tissue, HU 101.9 (5.5) 99.9 (4.5)
Visceral adipose tissue, HU 92.0 (4.3) 95.5 (4.5)
Adiponectin*, lg/mL 10.3 (6.6, 15.5) 5.1 (3.4, 8.0)
Leptin receptor*, ng/mL 18.2 (11.8, 24.8) 17.8 (11.7, 23.5)
Leptin*, ng/mL 13.5 (7.1, 26.6) 4.5 (2.7, 7.8)
FABP-4*, ng/mL 0.02 (0.01, 0.03) 0.02 (0.01, 0.02)
RBP-4* lg/mL 37.2 (30.8, 44.6) 43.4 (37.2, 50.5)
Fetuin-A*, mg/L 418.8 (314.7, 541.9) 398.9 (312.8, 509.4)
Current hormone replacement therapy, % 9.0% (74) N/A
Postmenopausal, % 24.7% (203) N/A
Current smoking†, % 14.1% (116) 14.8% (149)
Moderate to heavy alcohol use‡, % 14.4% (118) 16.0% (161)
Physical activity score 36.4 (6.1) 38.1 (8.9)
Data on means (SDs) or proportions (counts) are shown. FABP-4, fatty acid-binding protein 4; RBP-4, retinol-binding protein 4; HU, Hounsﬁeld unit.
*Values are shown as medians (25th, 75th percentiles) because of the skewed distribution.
†Deﬁned as ≥1 cigarette per day within the previous year.
‡Deﬁned as >7 drinks per week (women) or >14 drinks per week (men).
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ranged from 0.18 to 0.41) and lower levels of leptin and FABP-
4 (r values ranged from 0.69 to 0.44) in both sexes (all
P<0.001). In women, higher SAT density, but not VAT density,
was correlated with lower RBP-4 (r=0.18; P<0.001). In men,
higher SAT and VAT density were correlated with lower RBP-4
(r=0.14 for SAT, r=0.18 for VAT; both P<0.001). In both
women and men, higher VAT density, but not SAT density, was
weakly correlated with a lower level of fetuin-A (both sexes
r=0.07; P<0.05).
Multivariable-Adjusted Regression Models for
Abdominal Fat Density and Adipokines
The association of natural log-transformed biomarkers per
5-HU (1-SD) decrement in fat density is shown in Table 3
after covariate adjustment. Lower SAT and VAT density was
associated with lower adiponectin and leptin receptor levels,
but higher leptin and FABP-4 levels in both sexes (all
P<0.0001; Table 3). Lower SAT density was associated with
higher RPB-4 levels in both sexes; whereas lower VAT
density was associated with higher RPB-4 in men only (all
P<0.0001).
Next, the regression models were further adjusted for BMI,
waist circumference, or respective abdominal fat volumes
(SAT volume for SAT density model and VAT volume for VAT
density model; Table 3). When we additionally adjusted for
BMI or waist circumference, the association with fat density
generally decreased, but remained statistically signiﬁcant with
adiponectin, leptin, and FABP-4 in women; and with
adiponectin, leptin receptor, leptin, FABP-4, and RBP-4 in
men (all P<0.05). In women, after additional adjustment for
the respective abdominal fat volume, SAT density maintained
the associations with most of the biomarkers, as compared to
VAT density. In men, further adjustment for the respective CT
fat volume weakened the relationships between fat density
and metabolic biomarkers; however, all of these associations
remained statistically signiﬁcant (all P<0.005).
Secondary Analyses
We further tested for sex interactions between abdominal fat
density and metabolic biomarkers based on the multivariable
model. In general, the magnitude of the estimated
b-coefﬁcients between abdominal fat density and the given
biomarkers were similar between women and men (Table 3).
The only notable exceptions were SAT density with leptin
receptor (P=0.02) and leptin (P=0.001); and VAT density with
RBP-4 (P=0.03), where the magnitude of associations were
stronger in men, as compared to women.
Finally, we explored the association between abdominal fat
density and the circulating biomarkers with the respective
abdominal fat volumes. The multivariable-adjusted means of
each biomarker are presented in Figure and Figure S1
according to the sex-speciﬁc tertiles of SAT and VAT volume
by tertiles of SAT and VAT density. In general, higher tertiles
of SAT and VAT HU (ie, lower fat density), within greater
tertiles of respective fat volume (ie, greater fat volume), were
associated with relatively lower levels of adiponectin and
leptin receptor and higher levels of leptin, FABP-4, and RBP-4.
However, for women with the lowest adipose tissue volume
(SAT and VAT volume tertile 1), the inclusion of adipose tissue
volume changed the direction of the association of fat density
with leptin, leptin receptor, and RBP-4 (Figure and Figure S1).
Discussion
Principle Findings
In this cross-sectional, community-based observational study,
we related CT-derived abdominal adipose tissue attenuation
with a panel of circulating biomarkers released by adipose
tissue or liver. Lower abdominal fat density was associated
with adverse levels of circulating biomarkers; in particular,
lower adiponectin and leptin receptor levels and higher leptin,
FABP-4, and RBP-4 levels in both women and men. A majority
of these associations remained statistically signiﬁcant even
after additional adjustment for generalized adiposity (BMI),
central obesity (waist circumference), or respective abdominal
adipose tissue volumes. Moreover, lower adipose tissue
density with greater adipose tissue volumes was associated
with adverse levels of circulating biomarkers consistent with
greater cardiometabolic risk.
In the Context of the Current Literature
Greater accumulation of abdominal adipose tissue volumes is
associated with adverse concentrations of the circulating
Table 2. Age-Adjusted Sex-Speciﬁc Pearson Correlation
Coefﬁcients Between Abdominal Fat Density and Natural Log-
Transformed Adipokines
ln (Adipokines)
Women Men
SAT Density VAT Density SAT Density VAT Density
Adiponectin 0.30† 0.41† 0.18† 0.41†
Leptin receptor 0.18† 0.21† 0.24† 0.24†
Leptin 0.64† 0.50† 0.69† 0.59†
FABP-4 0.44† 0.48† 0.46† 0.49†
RBP-4 0.18† 0.02 0.14† 0.18†
Fetuin-A 0.06 0.07* 0.02 0.07*
FABP-4, fatty acid-binding protein 4; RBP-4, retinol-binding protein 4; SAT, subcutaneous
adipose tissue; VAT, visceral adipose tissue.
*P<0.05; †P<0.001.
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biomarkers of metabolic regulation.18–20 Yet, the quality of
abdominal adipose tissue assessed by radiographic imaging
techniques is relatively new, because only a few human-based
studies have been reported in recent years.13,17,21,22 To our
knowledge, only 1 previous study explored the associations
between SAT and VAT HU with a panel of adipose tissue-
derived biomarkers, referred to as adipokines, in an older
population (ages 65 and older) and in nonhuman primates.17
In that report, lower attenuation of CT fat was associated with
larger adipocyte size, as well as lower adiponectin and higher
leptin levels.17 Our study observed similar ﬁndings, and we
extend the literature to a more-comprehensive panel of
circulating biomarkers (including leptin receptor, FABP-4, and
RBP-4) and a broader age range of individuals. In our study, a
few signiﬁcant sex interactions between abdominal fat density
and metabolic biomarkers were detected. The most distinctive
sex interactions were identiﬁed between SAT density with
leptin receptors and leptin, where the associations were more
pronounced in men.
Previous studies have explored differences in adipogenesis
between women and men in the aspects of adipose tissue
cellularity.23–25 Progression to obesity was associated with
adipocyte hypertrophy in both women and men; and
adipocyte hyperplasia only in women.23 These ﬁndings
support the sexual dimorphism in the process of adipose
tissue remodeling. In addition, the size of the adipocyte
derived from SAT and VAT was larger in men than women,
even after adjusting for BMI.26 In our study, CT attenuation of
adipose tissue was implicated as a surrogate measure of fat
quality because lower attenuation of adipose tissue assessed
by CT corresponded to larger adipocyte size17 with highly
vascularized tissue.27 Of note, larger adipocytes were asso-
ciated with higher expression of leptin mRNA,26 which may
explain our ﬁndings of a more pronounced association
between fat density and leptin in men, as opposed to women.
However, further studies are necessary to elucidate the
differences in the mechanism in women and men linked with
adipose tissue quality and a broad array of adipokines.
Potential Physiological Mechanisms
Consistent with our a priori hypothesis, lower abdominal fat
density was associated with adverse concentrations of
circulating biomarkers, although the underlying mechanisms,
Figure. Multivariable-adjusted least-square means of adipokines according to the tertiles of subcutaneous adipose tissue volume and
density (HU) in women (A) and men (B). The multivariable-adjusted least-square means for each biomarker are given according to the
subcutaneous adipose tissue volume and density tertiles. P values for the linear trend are given for each of the fat volume tertiles. Tertile 3
corresponds to greater adipose tissue volumes and lower adipose tissue density (ie, more-negative CT fat attenuations), as compared to
tertile 1. Multivariable adjustment included age, hormone replacement therapy (women only), current smoking, alcohol use, and physical
activity score. CT, computed tomography; FABP-4, fatty acid-binding protein 4; HU, Hounsﬁeld unit; RBP-4, retinol binding protein 4.
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particularly the causal association between abdominal fat
density and the panel of biomarkers, remain unclear. There are
several potential mechanistic explanations for our ﬁndings. One
potential explanation is that lower attenuation of CT fat is an
indicator of adipose tissue with dense lipid content consisting
of large adipocytes that are ﬁlled with enlarged lipid
droplets.28,29 Enlarged adipocytes may reﬂect the insufﬁcient
proliferation of adipocytes attributed to impaired adiopogene-
sis in the state of obesity.30–33 Larger adipocyte size has been
related to increased metabolic activity and greater secretion of
adipocytokines, including adiponectin and leptin.34–36 Insulin-
stimulated glucose uptake and protein expressions that are
essential for lipid, fatty acid, and glucose metabolism appear to
differ between small and large adipocytes.37,38 Collectively,
dysfunctional secretion of adipokines induced by hypertrophied
adipocytes may provide insight into the pathophysiological
associations between hypertrophied adipocyte and adverse
cardiometabolic risk factors.39–43
Second, the low attenuation of CT fat may reﬂect adipose
tissue that is not affected by adipose tissue ﬁbrosis, which
allows the extracellular matrix remodeling of adipose tissues
to accommodate adipocyte expansion.21,44 This notion can be
supported by the association between elevated urinary
connective tissue growth factor (ie, a marker of systemic
ﬁbrosis) and higher CT fat attenuation.21 In line with this, a
dose-dependent reduction of collagen type VI a3 gene
expression (ie, gene that encodes ﬁbrotic extracellular matrix
protein) by leptin support the regulatory effect of leptin on
cellular ﬁbrosis.45 Taken together, the higher secretion of
leptin may suppress adipose tissue ﬁbrosis and subsequently
contribute to expandability of adipocytes.
Third, fat quality may be related to metabolic regulatory
biomarkers by systemic inﬂammation. Obesity is associated
with a chronic, low-grade inﬂammatory response with up-
regulation of proinﬂammatory adipokines that promote sys-
temic inﬂammation,46 such as leptin,47 FABP-4, RBP-4,47 and
fetuin-A48; and down-regulation of anti-inﬂammatory adipoki-
nes that reduce cellular inﬂammation,46 such as adiponec-
tin.20,47,49 It is plausible that altered adipose tissue quality, in
particular, adipocyte hypertrophy manifested by lipid overac-
cumulation,46,50 may trigger abnormal production of pro- and
anti-inﬂammatory adipokines and subsequently leads to a
generalized inﬂammatory state.51
In addition, there are other potential mechanisms that may
elaborate our ﬁndings. Lower attenuation of CT fat as a marker
of poor vascularity27 and cellular hypoxia13 may explain the
association between fat quality and adverse levels of adipo-
kines. More speciﬁcally, cellular hypoxia developed along with
adipocyte hypertrophy may be one of the key factors given that
secretion of adipose tissue-derived biomarkers is considerably
Figure. Continued.
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modiﬁed under hypoxic conditions.10 Importantly, reduced
vascularity is accompanied by more adipose tissue hypoxia as a
consequence of the progression to obesity.52 Taken globally,
these aforementioned ﬁndings add to the growing body of the
literature for the potent mechanistic explanations between fat
quality and adipokines.
Implications
Our ﬁndings suggest that abdominal SAT and VAT density, an
indirect measure of abdominal fat quality, may be a potential
indicator of cardiometabolic risk associated with metabolic
regulatory biomarkers. Accordingly, our data raise the possi-
bility of using abdominal adipose tissue quality assessed by
CT as an indicator to identify individuals at high risk for
developing cardiometabolic disease. Further studies are
necessary to explore the causal association between fat
density and levels of circulating biomarkers, as well as
whether the quality of abdominal adipose tissue has a
pathogenic impact on metabolism through its relationship
with metabolic regulatory biomarkers.
Strengths and Limitations
The strengths of this study include the use of a highly
reproducible and noninvasive measurement of abdominal CT
fat quality in a large, community-based sample. Limitations
include the cross-sectional and observational design that
precludes the temporal and causal inferences between
abdominal adipose tissue density and circulating adipokine
levels. The majority of the participants were white; our
ﬁndings cannot be generalized to other ethnicities. Serum
fatty acids and triacylglycerol were not measured. Finally, we
have used fat attenuation assessed by CT as a proxy for fat
quality. Mechanistic studies are necessary to better under-
stand the underlying cellular and histological characteristics
of this novel imaging measurement.
Conclusions
Low abdominal SAT and VAT density is associated with
adverse levels of circulating adipokines, suggestive of greater
cardiometabolic risk independent of generalized adiposity
(BMI), central obesity (waist circumference), and respective
abdominal SAT and VAT quantity.
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